How many insider trades does FilingIQ track for BNTX?

FilingIQ tracks 11 Form 4 insider transactions for BNTX (BioNTech SE), covering filings from Apr 22, 2026 onwards. 11 of those were filed in the last 90 days.

Are BNTX insiders net buyers or net sellers?

Across the full Form 4 history for BNTX, 0 transactions (0%) were open-market purchases and 1 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does BNTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is BNTX in?

BioNTech SE (BNTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.69B.

BNTX insider trading

NasdaqGS Healthcare

BioNTech SE — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 9%

Market cap

$26.69B

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Company website: www.biontech.de

BNTX insider activity at a glance

FilingIQ has scored 11 insider transactions for BNTX since Apr 22, 2026. The most recent filing in our index is dated May 12, 2026.

Across the full history, 0 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live BNTX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding BNTX

COMGEST GLOBAL INVESTORS S.A.S.

$33.48M · 0.7% of AUM

SECTOR GAMMA AS

$3.57M · 0.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for BNTX?: FilingIQ tracks 11 Form 4 insider transactions for BNTX (BioNTech SE), covering filings from Apr 22, 2026 onwards. 11 of those were filed in the last 90 days.
Are BNTX insiders net buyers or net sellers?: Across the full Form 4 history for BNTX, 0 transactions (0%) were open-market purchases and 1 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BNTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BNTX in?: BioNTech SE (BNTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.69B.

Methodology & sources

Every BNTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.